Evoking subclinical hypomania as a potential autism treatment - a hypothesis based on an up-to-date literature review

Main Article Content

Maciej Świerczek Krzysztof Nesterowicz


The growing number of children diagnosed with autism spectrum disorder (ASD) urges the scientific community to find a simple and cost-effective solution to this problem. Before 1990, the general population prevalence for autism was considered steady at 4–5/10,000 (1/2,000–1/2,500). However, recent studies on children in the United States have reported an ASD diagnosis in 1/91 3-17 year olds and 1/110 8 year olds.

A comprehensive literature review of over 700 articles on neurotransmitter levels and brain performance in autism and other psychiatric conditions was conducted to finally include 83 studies. The results of the search led us to the conclusion that autism is a state of the brain performance opposite in many aspects to mania (in particular hypomania), both behaviourally (in particular autism being characterized by social deficits and hypomania by hypersociability), neurochemically (e.g. low brain vasopressin, high cortisol in autism vs. high brain vasopressin, low cortisol in mania) and by activity of key brain areas (e.g. mirror neuron system, amygdala).

We hypothesize that instead of targeting separate neurotransmitter systems in autism, the focus should be on 'moving and locking' the brain into a subclinical hypomanic state when required. When in a subclinical hypomanic state, a patient's sociability (the key and most debilitating symptom of autism) should be massively improved. We have designed experiments which would test the above hypothesis.

Keywords: autism, mania, hypomania, mirror neuron system (MNS), amygdale

Article Details

How to Cite
ŚWIERCZEK, Maciej; NESTEROWICZ, Krzysztof. Evoking subclinical hypomania as a potential autism treatment - a hypothesis based on an up-to-date literature review. Medical Research Archives, [S.l.], v. 6, n. 1, jan. 2018. ISSN 2375-1924. Available at: <https://esmed.org/MRA/mra/article/view/1644>. Date accessed: 17 apr. 2024. doi: https://doi.org/10.18103/mra.v6i1.1644.
Review Articles



1. Miles J.H. Autism spectrum disorders—A genetics review. Genetics in Medicine. 2011; 13: 278–294.
2. World Health Organization. International Classification of Diseases (ICD-10). 2017.
3. Lord C., Jones R. Re-thinking the classification of autism spectrum disorders J Child Psychol Psychiatry. 2012 May; 53(5): 490–509.
4. World Health Organization .International Classification of Diseases (ICD-11 beta draft). 2017.
5. Lee M., Martin-Ruiz C., Graham A., Court J., Jaros E., Perry R., Iversen P., Bauman M., Perry E. Nicotinic receptor abnormalities in the cerebellar cortex in autism. Brain 2002; 125 (7): 1483-1495.
6. Onur O., Teksin G.,. Karsıdag C. A case of a varenicline-induced mania in a patient with the history of depression. European Psychiatry. 2016; Volume 33, Supplement: 411.
7. Leung J.G. Donepezil-induced mania. Consult Pharm. 2014; 29(3): 191-5.
8. Arnold L.E et al. Placebo-controlled pilot trial of mecamylamine for treatment of autism spectrum disorders. Journal of Child and Adolescent Psychopharmacology. 2012; 22(3): 198–205.
9. Nicolson R, Craven-Thuss B, Smith J. A prospective, open-label trial of galantamine in autistic disorder. J Child Adolesc Psychopharmacol. 2006; 16(5):621-9.
10. Barthelemy C., Bruneau N., Cottet-Eymard J.M., Domenech-Jouve J., Garreau B., Lelord G., Muh J.P., Peyrin L. Urinary free and conjugated catecholamines and metabolites in autistic children. J Autism Devel Disord.1988 ;18: 583-591.
11. Anderson C.J., Colombo J., Unruh K.E. Pupil and salivary indicators of autonomic dysfunction in autism spectrum disorder. Dev Psychobiol. 2013 ;55(5):465-82.
12. Mehler M.F., Purpura D.P. Autism, fever, epigenetics and the locus coeruleus. Brain Res Rev. 2009; 59(2): 388–392.
13. Harfterkamp M., Buitelaar J.K., Minderaa R.B., van de Loo-Neus G., van der Gaag R.-J., Hoekstra P.J. Long-Term Treatment with Atomoxetine for Attention-Deficit/Hyperactivity Disorder Symptoms in Children and Adolescents with Autism Spectrum Disorder: An Open-Label Extension Study. Journal of Child and Adolescent Psychopharmacology. 2013; 23(3): 194-199.
14. Hollander E., Kaplan A., Cartwright C., Reichman D. (2000). Venlafaxine in children, adolescents, and young adults with autism spectrum disorders: an open retrospective clinical report. J Child Neurol. 2000; 15(2): 132-5.
15. Kurita M., Nishino S., Numata Y., Okubo Y., Sato T. (2014). The noradrenaline metabolite MHPG is a candidate biomarker from the manic to the remission state in bipolar disorder I: a clinical naturalistic study. PLoS One. 2014 Jun 27; 9(6): e100634.
16. Henderson T.A., Hartman K. Aggression, Mania, and Hypomania Induction Associated with Atomoxetine. Pediatrics. September 2004, 114(3).
17. Bhargava Raman R.P., Suresh Bada Math, Gangadhar B.N. Venlafaxine-Induced Manic Switch in an Adolescent Patient: A Case Report. Prim Care Companion J Clin Psychiatry. 2007; 9(6): 470.
18. Hardy M.C., Lecrubier Y., Widlöcher D. Efficacy of clonidine in 24 patients with acute mania. Am J Psychiatry. 1986 Nov; 143(11): 1450-3.
19. Corbett B.A., Schupp C.W., Simon D., Ryan N., Mendoza S. Elevated cortisol during play is associated with age and social engagement in children with autism. Mol Autism. 2010; 1: 13.
20. Putnam S.K., Lopata C., Thomeer M.L., Volker M.A., Rodgers J.D. Salivary Cortisol Levels and Diurnal Patterns in Children with Autism Spectrum Disorder. J Dev Phys Disabil 2015 27: 453.
21. Valiengo L.L., Soeiro-de-Souza M.G., Marques A.H., Moreno D.H., Juruena M.F., Andreazza A.C., Gattaz W.F., Machado-Vieiraa R. Plasma cortisol in first episode drug-naïve mania: Differential levels in euphoric versus irritable mood. J Affect Disord. 2012 Apr; 138(0): 149–152.
22. Narayan M., Srinath S., Anderson G.M., Meundi D.B. Cerebrospinal fluid levels of homovanillic acid and 5-hydroxyindoleacetic acid in autism. Biol Psychiatry. 1993; 33(8-9): 630-5.
23. Lackner C.L., Bowman L.C., Sabbagh M.A. Dopaminergic functioning and preschoolers’ theory of mind. Neuropsychologia. 2010 May; 48(6): 1767-74.
24. Squillace M., Dodero L., Federici M., Migliarini S., Errico F., Napolitano F., Krashia P., Di Maio A., Galbusera A., Bifone A., Scattoni M.L., Pasqualetti M., Mercuri N.B., Usiello A., Gozzi A. Dysfunctional dopaminergic neurotransmission in asocial BTBR mice. Translational Psychiatry (2014) 4: 427.
25. Ernst M., Zametkin A.J., Matochik J.A., Pascualvaca D., Cohen R.M. Low medial prefrontal dopaminergic activity in autistic children. Lancet. 1997; 350(9078): 638.
26. Hollander E., Wasserman S., Swanson E.N., Chaplin W., Schapiro M.L., Zagursky K., Novotny S. A double-blind placebo-controlled pilot study of olanzapine in childhood/adolescent pervasive developmental disorder. J Child Adolesc Psychopharmacol. 2006; 16(5): 541-8.
27. Marcus R.N., Owen R., Kamen L., Manos G., McQuade R.D., Carson W.H., Aman M.G. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry. 2009; 48(11): 1110-9.
28. Chantal H., Demotes-Mainard J. (2002). Olanzapine-induced mania in bipolar disorders. J Psychiatry Neurosci. 2002; 27(3): 200–201.
29. Gerner R.H. et al.. CSF neurochemistry in depressed, manic, and schizophrenic patients compared with that of normal controls. Am J Psychiatry. 1984; 141(12): 1533-40.
30. Sultzer D.L., Cummings J.L. Drug-induced mania--causative agents, clinical characteristics and management. A retrospective analysis of the literature. Med Toxicol Adverse Drug Exp. 1989; 4(2): 127-43.
31. Singh A., Althoff R., Martineau R.J., Jacobson J. Pramipexole, ropinirole, and mania in Parkinson's disease. Am J Psychiatry. 2005 ; 162(4): 814-5.
32. Reeves R.R., McBride W.A., Brannon G.E.. Olanzapine-induced mania. J Am Osteopath Assoc. 1998; 98(10): 549-50.
33. Kavoor A.R., Mitra S., Mondal S.K., Das B. Risperidone-induced mania: An emergent complication of treatment. J Pharmacol Pharmacother. 2014 ; 5(4): 258–260.
34. Donohue A. (2010). First Manic Episode in a 55-Year-Old Man After Initiation of Aripiprazole. Psychiatry (Edgmont). 2010; 7(4): 37–39.
35. Rossi P.G., Posar A., Parmeggiani A., Pipitone E., D'Agata M. Niaprazine in the treatment of autistic disorder. J Child Neurol. 1999; 14(8): 547-50.
36. Linday L.A. Oral famotidine: a potential treatment for children with autism. Med Hypotheses. 1997; 48(5): 381-6.
37. Pal H., Kumar R., Bhushan S., Berry N. Psychiatric co-morbidity associated with pheniramine abuse and dependence. Indian J Psychiatry. 2005 Jan-Mar; 47(1): 60–62.
38. von Einsiedel R.W., Roesch-Ely D., Diebold K., Sartor K., Mundt C., Bergemann N. H(2)-histamine antagonist (famotidine) induced adverse CNS reactions with long-standing secondary mania and epileptic seizures. Pharmacopsychiatry. 2002 ; 35(4): 152-4.
39. Posey D.J., Kem D.L., Swiezy N.B., Sweeten T.L., Wiegand R.E., McDougle C.J. A pilot study of D-cycloserine in subjects with autistic disorder. Am J Psychiatry. 2004; 161(11): 2115-7.
40. Horder J., Lavender T., Mendez M.A., O'Gorman R., Daly E., Craig M.C., Lythgoe D.J., Barker G.J., Murphy D.G. Reduced subcortical glutamate/glutamine in adults with autism spectrum disorders: a [¹H]MRS study. Transl Psychiatry. 2013 ; 3: e279.
41. Hoekstra R., Fekkes D., Loonen A.J., Pepplinkhuizen L., Tuinier S., Verhoeven W.M. Bipolar mania and plasma amino acids: increased levels of glycine. Eur Neuropsychopharmacol. 2006; 16(1): 71-7.
42. Michael N., Erfurth A., Ohrmann P., Gössling M., Arolt V., Heindel W., Pfleiderer B. Acute mania is accompanied by elevated glutamate/glutamine levels within the left dorsolateral prefrontal cortex. Psychopharmacology (Berl). 2003 ; 168(3): 344-6.
43. Serra G., Demontis F., Serra F., De Chiara L., Spoto A., Girardi P., Vidotto G., Serra Gi. Memantine: New prospective in bipolar disorder treatment. World J Psychiatry. 2014; 4(4): 80–90.
44. Panksepp J. (1979). A neurochemical theory of autism. Trends in Neurosciences. 1979; 2:174–177.
45. Tordjman S., Anderson G.M., McBride P.A., Hertzig M.E., Snow M.E., Hall L.M., Thompson S.M., Ferrari P., Cohen D.J. Plasma beta-endorphin, adrenocorticotropin hormone, and cortisol in autism. J Child Psychol Psychiatry. 1997; 38(6): 705-15.
46. Cazzullo A.G., Musetti M.C., Musetti L., Bajo S., Sacerdote P., Panerai A. Beta-endorphin levels in peripheral blood mononuclear cells and long-term naltrexone treatment in autistic children. Eur Neuropsychopharmacol. 1999; 9(4): 361-6.
47. Shariat S.V., Hosseinifard Z., Taban M., Shabani A. Mania precipitated by opioid withdrawal: a retrospective study. Am J Addict. 2013; 22(4): 338-43.
48. Yatawara C.J., Einfeld S.L., Hickie I.B., Davenport T.A., Guastella A.J. The effect of oxytocin nasal spray on social interaction deficits observed in young children with autism: a randomized clinical crossover trial. Molecular Psychiatry 2016; 21: 1225–1231;
49. Danforth A.L. (2013). Courage, connection, and clarity: A mixed-methods collective-case study of MDMA (ecstasy) experiences of autistic adults. Doctoral dissertation. Institute of Transpersonal Psychology, 2013, 268 pages. [Retrieved from ProQuest Dissertations and Theses. (UMI No. 3401141)].
50. Turan T., Uysal C., Asdemir A., Kılıç E. May oxytocin be a trait marker for bipolar disorder? Psychoneuroendocrinology. 2013; 38(12): 2890-6.
51. Adamsen D., Ramaekers V., Ho H.T., Britschgi C., Rüfenacht V., Meili D., Bobrowski E., Philippe P., Nava C., Van Maldergem L., Bruggmann R., Walitza S., Wang J., Grünblatt E., Thöny B. Autism spectrum disorder associated with low serotonin in CSF and mutations in the SLC29A4 plasma membrane monoamine transporter (PMAT) gene. Mol Autism. 2014; 5: 43.
52. Posey D.J., Guenin K.D., Kohn A.E., Swiezy N.B., McDougle C.J. A naturalistic open-label study of mirtazapine in autistic and other pervasive developmental disorders. J Child Adolesc Psychopharmacol. 2001; 11(3): 267-77.
53. Gordon C.T., State R.C., Nelson J.E., Hamburger S.D., Rapoport J.L. A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch Gen Psychiatry. 1993; 50(6): 441-7.
54. Fatemi S.H., Realmuto G.M., Khan L., Thuras P.D. Fluoxetine in Treatment of Adolescent Patients with Autism: A Longitudinal Open Trial. J Autism Dev Disord 1998; 28: 303.
55. Steingard R.J., Zimnitzky B., DeMaso D.R., Bauman M.L., Bucci J.P. Sertraline treatment of transition-associated anxiety and agitation in children with autistic disorder. J Child Adolesc Psychopharmacol. 1997; 7(1): 9-15.
56. Bhanji N.H., Margolese H.C., Saint-Laurent M., Chouinard G. Dysphoric mania induced by high-dose mirtazapine: a case for 'norepinephrine syndrome'? Int Clin Psychopharmacol. 2002; 17(6): 319-22.
57. Ramasubbu R. (2001). Dose-response relationship of selective serotonin reuptake inhibitors treatment-emergent hypomania in depressive disorders. Acta Psychiatr Scand. 2001; 104(3): 236-8.
58. Lutchmaya S., Baron-Cohen S., Raggatt P. (2001). Foetal testosterone and vocabulary size in 18- and 24-month-old infants. Infant Behavior and Development. 2001; 24(4): 418–424.
59. Croonenberghs J., Van Grieken S., Wauters A., Van West D., Brouw L., Maes M., Deboutte D. (2010). Serum testosterone concentration in male autistic youngsters. Neuro Endocrinol Lett. 2010; 31(4): 483-8.
60. Trenton A.J., Currier G.W. Behavioural manifestations of anabolic steroid use. CNS Drugs. 2005; 19(7): 571-95.
61. Carson D.S., Garner J.P., Hyde S.A., Libove R.A., Berquist S.W., Hornbeak K.B., Jackson L.P., Sumiyoshi R.D., Howerton C.L., Hannah S.L., Partap S., Phillips J.M., Hardan A.Y., Parker K.J. Arginine Vasopressin Is a Blood-Based Biomarker of Social Functioning in Children with Autism. PLoS One. 2015 Jul; 10(7):e0132224.
62. Zhang R., Jia M.X., Zhang J.S., Xu X.J., Shou X.J., Zhang X.T., Li L., Li N., Han S.P., Han J.S. Transcutaneous electrical acupoint stimulation in children with autism and its impact on plasma levels of arginine-vasopressin and oxytocin: a prospective single-blinded controlled study. Res Dev Disabil. 2012; 33(4): 1136-46.
63. Sørensen P.S., Gjerris A., Hammer M. Cerebrospinal fluid vasopressin in neurological and psychiatric disorders. J Neurol Neurosurg Psychiatry. 1985 Jan; 48(1): 50-7.
64. Legros J.J., Ansseau M. Increased basal plasma vasopressin-neurophysin in mania. Horm Res. 1989; 31(1-2): 55-8.
65. Rizzolatti G., Craighero L. The mirror-neuron system. Annual Review of Neuroscience. 2004; 27(1): 169–192.
66. Keysers C. Mirror Neurons. Current Biology. 2010; 19 (21): 971–973.
67. Keysers C. The Empathic Brain. (2011).
68. Rizzolatti G., Fadiga L. Resonance Behaviors and Mirror Neurons. Italiennes de Biologie. 1999; 137: 85–100.
69. Molenberghs P, Cunnington R, Mattingley J.Is the mirror neuron system involved in imitation? A short review and meta-analysis. Neuroscience & Biobehavioral Reviews. 2009; 33(1): 975–980.
70. Oberman L.M., Hubbard E.M., McCleery J.P., Altschuler E.L., Ramachandran V.S., Pineda J.A. EEG evidence for mirror neuron dysfunction in autism spectrum disorders. Brain Res Cogn Brain Res. 2005; 24(2): 190-8.
71. Enticott P.G., Kennedy H.A., Rinehart N.J., Tonge B.J., Bradshaw J.L., Taffe J.R., Daskalakis Z.J., Fitzgerald P.B. Mirror neuron activity associated with social impairments but not age in autism spectrum disorder. Biol Psychiatry. 2012; 71(5): 427-33.
72. Mehta U.M., Basavaraju R., Thirthalli J. Mirror neuron activity and symptom severity in drug-naïve mania - a transcranial magnetic stimulation study. Brain Stimul. 2014; 7(5): 757-9.
73. Zhao X., Zhang P., Fu L., Maes J.H. Attentional biases to faces expressing disgust in children with autism spectrum disorders: an exploratory study. Sci Rep. 2016; 6: 19381.
74. Eack S.M., Mazefsky C.A., Minshew N.J. Misinterpretation of facial expressions of emotion in verbal adults with autism spectrum disorder. Autism. 2015; 19(3): 308-15.
75. Lembke A., Ketter T.A. Impaired recognition of facial emotion in mania. Am J Psychiatry. 2002 Feb; 159(2): 302-4.
76. Lennox B.R., Jacob R., Calder A.J., Lupson V., Bullmore E.T. Behavioural and neurocognitive responses to sad facial affect are attenuated in patients with mania. Psychol Med. 2004; 34(5): 795-802.
77. Amunts K., Kedo O., Kindler M., Pieperhoff P., Mohlberg H., Shah N.J., Habel U., Schneider F., Zilles K.Cytoarchitectonic mapping of the human amygdala, hippocampal region and entorhinal cortex: intersubject variability and probability maps. Anat Embryol (Berl). 2005: 210(5–6): 343–52.
78. Swartz J.R., Wiggins J.L., Carrasco M., Lord C., Monk C.S. (2012). Amygdala habituation and prefrontal functional connectivity in youth with autism spectrum disorders. J Am Acad Child Adolesc Psychiatry. 2013; 52(1): 84-93.
79. Weng S.J. Neural activation to emotional faces in adolescents with autism spectrum disorders. J Child Psychol Psychiatry. 2011; 52(3): 296-305.
80. Kleinhans N.M., Richards T., Weaver K., Johnson L.C., Greenson J., Dawson G., Aylward E. Association between amygdala response to emotional faces and social anxiety in autism spectrum disorders. Neuropsychologia. 2010; 48(12): 3665-70.
81. Lennox B.R., Jacob R., Calder A.J., Lupson V., Bullmore E.T. Behavioural and neurocognitive responses to sad facial affect are attenuated in patients with mania. Psychol Med. 2004; 34(5): 795-802.
82. Bermpohl F., Dalanay U., Kahnt T., Sajonz B., Heimann H., Ricken R., Stoy M., Hägele C., Schlagenhauf F., Adli M., Wrase J., Ströhle A., Heinz A., Bauer M. A preliminary study of increased amygdala activation to positive affective stimuli in mania. Bipolar Disord. 2009; 11(1): 70-5.
83. Scappa S., Teverbaugh P., Ananth J. Episodic tardive dyskinesia and parkinsonism in bipolar disorder patients. Can J Psychiatry. 1993; 38(10): 633-4.